Nippon Life Global Investors Americas Inc. cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,930 shares of the biopharmaceutical company’s stock after selling 4,550 shares during the period. Nippon Life Global Investors Americas Inc.’s holdings in Regeneron Pharmaceuticals were worth $12,935,000 at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. Acadian Asset Management LLC boosted its holdings in Regeneron Pharmaceuticals by 2,132.8% during the second quarter. Acadian Asset Management LLC now owns 1,496 shares of the biopharmaceutical company’s stock worth $735,000 after buying an additional 1,429 shares in the last quarter. Ingalls & Snyder LLC boosted its holdings in Regeneron Pharmaceuticals by 15.3% during the second quarter. Ingalls & Snyder LLC now owns 6,628 shares of the biopharmaceutical company’s stock worth $3,255,000 after buying an additional 879 shares in the last quarter. Welch & Forbes LLC boosted its holdings in Regeneron Pharmaceuticals by 10.1% during the second quarter. Welch & Forbes LLC now owns 599 shares of the biopharmaceutical company’s stock worth $294,000 after buying an additional 55 shares in the last quarter. Korea Investment CORP boosted its holdings in Regeneron Pharmaceuticals by 7,615.1% during the second quarter. Korea Investment CORP now owns 22,991 shares of the biopharmaceutical company’s stock worth $11,292,000 after buying an additional 22,693 shares in the last quarter. Finally, Princeton Capital Management Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.6% during the second quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock worth $1,233,000 after buying an additional 15 shares in the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.
A number of brokerages recently weighed in on REGN. Morgan Stanley restated an “equal weight” rating and set a $450.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 23rd. Canaccord Genuity restated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, October 16th. Barclays cut shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Oppenheimer restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 27th. Finally, Leerink Swann restated an “outperform” rating and set a $580.00 target price (up from $573.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $467.84.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a net margin of 23.17% and a return on equity of 25.73%. The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the prior year, the firm earned $3.13 EPS. The company’s revenue was up 23.0% compared to the same quarter last year. equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current year.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $475.00, for a total value of $712,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Charles A. Baker sold 2,000 shares of the stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $900,000.00. Following the completion of the sale, the director now owns 11,000 shares of the company’s stock, valued at approximately $4,950,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,352 shares of company stock valued at $2,037,772. Insiders own 10.80% of the company’s stock.
WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/04/regeneron-pharmaceuticals-inc-regn-stake-lessened-by-nippon-life-global-investors-americas-inc.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).
What are top analysts saying about Regeneron Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regeneron Pharmaceuticals Inc. and related companies.